91.6% is a good efficacy. Do they have plans to test it against other variants (E501Y mutation)? Ideally this + the adenovirus based AZD122 seems to be the best

91.6% is a good efficacy. Do they have plans to test it against other variants (E501Y mutation)? Ideally this + the adenovirus based AZD122 seems to be the best combination of (efficacy, affordablility, and logistically feasibility) end for the pandemic. https://www.gavi.org/vaccineswork/coronavirus-why-combining-oxford-vaccine-russias-sputnik-v-vaccine-could-make-it https://www.gavi.org/vaccineswork/coronavirus-why-combining-... is another such article which talks about it.